Create Free Account

By creating account you will get access to hot stocks & personalised emails

Elixinol Wellness Limited

Healthcare AU EXL

0.003AUD
-0.0005(14.29%)

Last update at 2024-07-26T00:02:00Z

Day Range

0.0030.003
LowHigh

52 Week Range

0.0030.01
LowHigh

Fundamentals

  • Previous Close 0.0035
  • Market Cap3.96M
  • Volume86
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.92100M
  • Revenue TTM8.27M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 2.98M
  • Diluted EPS TTM-0.01

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -10.56900M -17.09000M -100.27800M -73.61600M -0.49700M
Minority interest - - -0.02800M -0.03100M -0.03100M
Net income -10.57100M -17.02500M -104.47800M -66.41200M -0.86000M
Selling general administrative 8.08M 12.95M 17.54M 19.73M 10.76M
Selling and marketing expenses 2.29M 3.68M 7.17M 12.25M 7.41M
Gross profit 3.24M 4.90M 6.67M 15.62M 19.96M
Reconciled depreciation 0.72M 2.30M 3.21M 2.45M 0.82M
Ebit -9.01200M -11.66800M 49.12M -24.74200M -0.49700M
Ebitda -8.29100M -10.17800M 52.33M -22.29100M 0.33M
Depreciation and amortization 0.72M 1.49M 3.21M 2.45M 0.82M
Non operating income net other - - - - -
Operating income -9.01200M -11.66800M 49.12M -24.74200M -0.97400M
Other operating expenses 17.06M 24.95M 40.34M 50.95M 38.10M
Interest expense -0.04900M 5.42M 149.43M 0.12M 0.00000M
Tax provision 0.00200M -0.06500M 4.20M -7.62000M 0.36M
Interest income 0.02M 0.00800M 0.10M 1.75M 0.70M
Net interest income -0.04900M -0.06300M 0.05M 0.55M 0.44M
Extraordinary items - - 0.00000M -17.07400M -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.00200M -0.06500M 4.20M -7.20400M 0.36M
Total revenue 7.05M 9.34M 15.01M 27.18M 37.13M
Total operating expenses 13.24M 20.50M 31.99M 39.38M 20.93M
Cost of revenue 3.82M 4.44M 8.34M 11.56M 17.18M
Total other income expense net -1.55700M -5.42200M -149.39900M -48.87400M 0.48M
Discontinued operations - - - -2.55900M -1.20400M
Net income from continuing ops -10.57100M -27.85300M -104.47800M -65.99700M -0.86000M
Net income applicable to common shares -10.57100M -17.02500M -104.50600M -82.92800M -0.86000M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 11.71M 13.48M 25.33M 42.47M 121.07M
Intangible assets - 0.15M 0.46M 0.92M 11.77M
Earning assets - - - - -
Other current assets 2.08M 0.17M 0.17M 0.20M 6.73M
Total liab 5.25M 4.33M 6.25M 6.82M 9.69M
Total stockholder equity 6.46M 9.16M 19.08M 35.65M 111.41M
Deferred long term liab - - - - -
Other current liab 1.64M 1.35M 1.10M 0.91M 1.94M
Common stock 222.57M 218.12M 218.06M 217.73M 188.77M
Capital stock - 218.12M 218.06M 217.73M 188.77M
Retained earnings -226.15300M -218.64600M -208.07500M -191.05000M -86.95900M
Other liab - - - 0.09M 0.04M
Good will - - 0.00000M 0.00000M 27.14M
Other assets 0.00000M 0.08M 0.18M 0.00000M 4.31M
Cash 0.71M 2.86M 12.65M 27.74M 20.24M
Cash and equivalents - - - - 20.24M
Total current liabilities 4.99M 3.44M 4.71M 5.00M 6.01M
Current deferred revenue 0.52M - 1.07M 1.35M 0.09M
Net debt 0.55M -0.96000M -9.93400M -24.99900M -15.61400M
Short term debt 1.07M 1.02M 1.18M 0.92M 0.99M
Short long term debt - 0.32M 0.43M - -
Short long term debt total 1.26M 1.90M 2.71M 2.74M 4.63M
Other stockholder equity - 9.09M 9.09M 8.97M 0.08M
Property plant equipment - 1.11M 2.48M 3.88M 17.01M
Total current assets 8.18M 9.31M 19.59M 35.35M 51.36M
Long term investments - 2.83M 2.62M 2.32M 8.40M
Net tangible assets - 9.01M 18.61M 34.73M 71.42M
Short term investments - 0.17M 0.17M 0.09M 0.10M
Net receivables 1.72M 3.97M 2.97M 1.19M 1.54M
Long term debt - 0.25M 0.25M 0.25M 0.00000M
Inventory 3.66M 1.74M 2.20M 4.74M 22.40M
Accounts payable 1.76M 1.08M 1.36M 1.82M 2.99M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 10.04M 9.68M 9.09M 8.97M 9.52M
Additional paid in capital - - - - -
Common stock total equity - - - 217.73M 188.77M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2.35M 0.08M 0.18M - 1.17M
Deferred long term asset charges - - - - -
Non current assets total 3.54M 4.17M 5.74M 7.12M 69.71M
Capital lease obligations - 1.33M 2.04M 2.49M 4.67M
Long term debt total - 0.82M 1.47M 1.73M 3.68M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.86900M -0.01000M 2.55M -7.15700M -3.59300M
Change to liabilities -0.90300M -0.61400M 3.80M -8.92300M 5.11M
Total cashflows from investing activities -0.86900M 0.17M 2.55M -17.93200M -8.50900M
Net borrowings -0.75700M -1.04700M -1.41400M -0.72900M -0.03800M
Total cash from financing activities -0.75700M -1.15700M 27.55M 46.44M 37.77M
Change to operating activities 0.23M 0.35M 1.19M -2.65200M -3.23400M
Net income -10.57100M -27.85300M -104.50600M -82.92800M -0.86000M
Change in cash -9.78500M -15.09400M 7.37M -22.54900M 24.09M
Begin period cash flow 12.65M 27.74M 20.37M 42.92M 18.83M
End period cash flow 2.86M 12.65M 27.74M 20.37M 42.92M
Total cash from operating activities -9.85000M -14.07100M -22.62100M -51.06600M -5.25200M
Issuance of capital stock - - 31.48M 50.00M 40.00M
Depreciation 0.72M 1.49M 3.21M 2.45M 0.82M
Other cashflows from investing activities -0.85700M 0.46M 2.88M -6.78600M -0.01300M
Dividends paid - - - - -
Change to inventory 0.23M -0.24400M -2.15500M -25.35400M -4.50600M
Change to account receivables 0.14M -2.01400M 0.71M 1.61M -2.23200M
Sale purchase of stock - -0.11000M -2.51900M -2.82700M -2.18800M
Other cashflows from financing activities -0.75700M -1.04700M -1.41400M -0.72900M -5.25200M
Change to netincome 1.52M 4.02M 75.52M 64.57M -0.03400M
Capital expenditures 0.01M 0.29M 0.33M 11.15M 4.91M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.39M 0.41M 0.47M 0.68M 0.33M
Stock based compensation - - - - -
Other non cash items 9.85M 26.36M 101.29M 80.48M 0.04M
Free cash flow -9.86200M -14.36300M -22.94900M -62.21200M -10.15900M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EXL
Elixinol Wellness Limited		 -0.0005 14.29% 0.003 - - 0.79 1.11 0.93 -1.1328
AFP
AFT Pharmaceuticals Ltd		 -0.04 1.37% 2.89 21.54 17.06 1.79 4.41 2.18 16.66
VLS
Vita Life Sciences Ltd		 - -% 2.25 13.24 - 1.73 2.97 1.41 7.98
NXS
Next Science Ltd		 -0.01 3.45% 0.28 - 128.21 4.47 5.03 3.90 -5.9908
PER
Percheron Therapeutics Limited		 0.002 2.70% 0.08 - - 31.54 4.38 347.00 -4.319

Reports Covered

Stock Research & News

View All

Profile

Elixinol Wellness Limited, through its subsidiaries, engages in the manufacture and distribution of hemp derived nutraceuticals, skincare, and food products in the Americas, Europe, and Australia. It offers hemp derived cannabidiol and food products, dietary supplements, topicals, and skincare products. The company was formerly known as Elixinol Global Limited and changed its name to Elixinol Wellness Limited in May 2021. The company was incorporated in 2017 and is headquartered in Sydney, Australia.

Elixinol Wellness Limited

680 George Street, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Mr. Ronald Dufficy BEC, FCPA Interim Global Chief Exec. Officer NA
Ms. Josephine Lorenz Global CFO & Group Financial Controller NA
Glen Zurcher Account Director of Investor Relations Department NA
Ms. Teresa Cleary Gen. Counsel & Company Sec. NA
Mr. Rob Hasselman Pres of Americas NA
Ms. Beata Silber Global Head of R&D and Innovation NA
Ms. Kim Bradley-Ware Joint Company Sec. NA
Mr. Ronald Dufficy BEC, FCPA Group CEO, MD & Director NA
Ms. Josephine Lorenz Global CFO, Group Financial Controller & Joint Company Secretary NA
Mr. Rob Hasselman President of Americas NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.